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Abstract
Background: Prostate cancer is a frequent finding in man. In dogs, malignant disease of the
prostate is also of clinical relevance, although it is a less common diagnosis. Even though there are
numerous differences in origin and development of the disease, man and dog share many similarities
in the pathological presentation. For this reason, the dog might be a useful animal model for
prostate malignancies in man.
Although prostate cancer is of great importance in veterinary medicine as well as in comparative
medicine, there are only few cell lines available. Thus, it was the aim of the present study to
determine whether the formerly established prostate carcinoma cell line CT1258 is a suitable tool
for in vivo testing, and to distinguish the growth pattern of the induced tumours.
Methods: For characterisation of the in vivo behaviour of the in vitro established canine prostate
carcinoma cell line CT1258, cells were inoculated in 19 NOD.CB17-PrkdcScid/J (in the following:
NOD-Scid) mice, either subcutaneously or intraperitoneally. After sacrifice, the obtained
specimens were examined histologically and compared to the pattern of the original tumour in the
donor.
Cytogenetic investigation was performed.
Results: The cell line CT 1258 not only showed to be highly tumourigenic after subcutaneous as
well as intraperitoneal inoculation, but also mimicked the behaviour of the original tumour.
Conclusion: Tumours induced by inoculation of the cell line CT1258 resemble the situation in
naturally occurring prostate carcinoma in the dog, and thus could be used as in vivo model for future
studies.
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Background
Only few species are known to spontaneously develop
prostatic neoplasia; therefore the search for a suitable ani-
mal model for this disease is difficult. Currently, the dog
is used as in vivo model for prostate malignancies in man,
since it shows a similar metastatic pattern as well as age
dependent development of malignant prostatic lesions [1-
3]. Whereas prostate cancer is a frequent finding in man
and even one of the leading causes of death in the Western
world, it is less common in the dog. The prevalence is only
0. 2%–0. 6% [20]. Since this number is based on necropsy
findings, the true number might be higher [4,5]. Although
the relative number appears to be quite low, it results in
an absolute count of estimated 60,000–180,000 affected
dogs in the USA, 6,000–18,000 dogs in the UK, and
5,300–15,900 dogs in Germany, based on population.
Although there are some reports observing a permissive or
protective effect of androgens [6-10], androgens do not
seem to have an influence on development, growth, or
metastasis in prostate carcinoma in dogs. Other than in
human medicine, the diagnosis is usually made at a very
late state of the disease, since for dogs no screening tests
are available as there are for man [13]. Therefore treat-
ment options for prostate cancer in the dog are limited
and mostly remain to be palliative.
Despite the rather high incidence of prostate carcinoma in
man, there are only three cell lines of human prostate car-
cinoma and their sub lines available. Thus, it is not sur-
prising that there are only occasional reports about cell
lines of canine prostatic carcinoma [11-13]. Hence the
purpose of the present study was to establish an animal
model, using the recently described cell line CT1258,
which has been derived from a spontaneous canine pros-
tate carcinoma [14,15]. Special attention was directed
towards comparison of the clinical behaviour of the
induced tumour in mice to the spontaneous tumour in
the donor, as well as histological comparison. A compari-
son of the Ki67 index was performed in order to be able
to address a potential change in proliferation. The Ki67
Index has been described to be associated with a poor out-
come in human prostate cancer [18].
Methods
Donor
The cell line was derived from a prostatic tumour of a
Briard, 10 years, male intact, which had been presented at
the Small Animal Clinic of the University of Veterinary
Medicine Hanover, Germany. The dog had a two week
history of dyschezia, gain of abdominal girth, polydipsia,
and loss of appetite. Clinical examination revealed an
undulating and strained abdomen. Abdominal radio-
graphs showed a highly reduced perceptibility of detail.
On abdominal ultrasound an enlarged prostate could be
detected, which contained several cysts.
Explorative laparatomy was performed and about 3000
ml abdominal fluid were obtained; the prostate itself was
highly enlarged and several miliary masses were found in
the mesentery. There was no evidence of contact metas-
tases to abdominal organs or distant metastases to the
lung. Biopsies have been taken under general anaesthesia;
the cytological diagnosis of a highly malignant adenocar-
cinoma of the prostate resulted in euthanasia ad tabulam.
Prior to euthanasia, biopsies have been taken for further
histological examination and for cell culture. Histological
staining and immunohistochemical staining as well as
cytogenetic analysis was performed as described below.
Cell line
The cell culture conditions, as well as the characteristics of
the canine prostate carcinoma cell line CT1258 have been
described previously [15].
Animals
This study involved 19 NOD-Scid mice (10 male, 9
female). All animals were bred and maintained in a pro-
tected environment at the Institute of Laboratory Animal
Science of the Hanover Medical School. The mice were fed
autoclaved food and water ad libitum, any manipulation
was performed in a laminar flow hood. The animals were
observed on a daily basis and sacrificed depending on the
clinical condition and the size of detectable tumour,
respectively. The tumours were allowed to grow up to a
diameter of 10 mm. Additional criteria for euthanasia
were ulceration of subcutaneous masses, a reduced level
of activity of the mice, and the loss of appetite. The ani-
mals were humanely sacrificed by cervical dislocation
after inhalation of > 70% carbon dioxide. The study was
approved by the Lower Saxony State Office of Consumer
Security and Food Safety (33-42502-05/950), the ethical
approval was sought from the University of Veterinary
Medicine Hanover.
Inoculation of Cells
The cells were harvested from the culture flasks with 1 ml
of TrypLE Express (Invitrogen, Karlsruhe, Germany) and
incubated at room temperature for 1 minute. L-199
medium (Invitrogen, Karlsruhe, Germany) supplemented
with 20% FCS was added and the cells were centrifuged at
350 g for 15 minutes. The cell pellet was washed twice
with PBS. The cells were resuspended in 200 μl PBS;
immediately before application the suspension was aspi-
rated into Insulin-Syringes (BD Micro-Fine, BD, Heidel-
berg, Germany) and inoculated either subcutaneously
into the left flank of the animals or intraperitoneally.BMC Cancer 2008, 8:240 http://www.biomedcentral.com/1471-2407/8/240
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For subcutaneous inoculation, the animals received 1 ×
106 cells. For intraperitoneal application, mice received
either 1 × 105 or 5 × 105 cells. The 19 NOD-Scid mice were
subdivided into two groups: One group consisted of four
female and five male mice, the animals received 1 ×
106cells subcutaneously each. The second group consisted
of five male and five female animals, cells were inoculated
intraperitoneally. Four of them (2 male, 2 female)
received 1 × 105 cells; six animals (3 male, 3 female)
received 5 × 105 cells, respectively.
Necropsy and histological staining
Necropsy was performed immediately after death had
occurred. Lung, liver, spleen, kidneys, gonads, bowel, and
detected masses were removed, fixed in 10% buffered for-
malin, paraffin embedded, sectioned, and stained with
hematoxylin and eosin; immunohistochemical staining
for Ki67 was performed, using the monoclonal antibody
MIB-1 (Dianova, Hamburg, Germany) in a dilution of
1:100. The paraffin sections were pretreated in a micro-
wave oven for 20 minutes in citrate buffer solution, pH 6.
The secondary antibody was a biotinylated goat-α-mouse
antibody, for detection, the Vectastain ABC-Kit (Vector
Laboratories, Burlingame, USA) has been used. The Ki67
Index was determined by detecting the fraction of Ki67
positive stained cells in total 500 cells. This was per-
formed in the original tumour, as well as in the induced
tumours. Intestinal mucosa served as positive control. In
addition, tumour samples of each mouse were obtained
in liquid nitrogen for real time RT-PCR and in Hank's
Medium for further in vitro culturing and Cytogenetic
analysis. In order to address the growth pattern, the origi-
nal canine tumour and the murine tumours have been
classified based upon the presence of glandular, urothe-
lial, squamoid, or sarcomatoid differentiation.
Cytogenetic analysis
For cytogenetic investigation, cells have been processed as
described previously [15]. Tissue was transferred to liquid
nitrogen immediately after dissection and stored at -70°C
until examination.
Statistics
This study was intended to be descriptive rather than sta-
tistically significant. However, a paired student's t-test was
performed. A P-value < 0.05 was considered to be signifi-
cant.
Results
Pathological and histological examination
Original canine tumour
On histological examination the tumour showed to be
consisting of poorly differentiated cells with numerous
signs of malignancy. A strong anisocytosis, numerous cells
with multiple nuclei, anisokaryosis, multiple mitotic fig-
ures, to some extent atypical mitotic figures, and a varying
nucleus: plasma ratio could be detected. The tumour
showed a compact growth with glandular differentiation.
The Ki67 index was 43%.
Subcutaneous tumours
For analysis of duration until sacrifice of the mice, only
those individuals were considered that were sacrificed due
to tumour burden. All female mice and four of five male
mice developed a detectable tumour mass after subcuta-
neous inoculation of 1 × 106 cells of the canine prostate
carcinoma cell line CT1258 (Table 1). One mouse with-
out detectable tumour growth was sacrificed due to bad
clinical condition; necropsy revealed a mass of the thy-
mus, histologically addressed as thymoma. In the remain-
ing mice tumours were allowed to grow up to a size of 5–8
mm, which lasted 20 to 42 days (mean 25.37 days,
median 22 days). Gender distribution showed a mean
value of 28.75, median 26.5 days for female mice, and a
mean and a median of 22 days for the males. None of the
mice showed any signs of metastasis or of invasive growth
pathologically or histologically; except for the mouse that
did not develop any tumour mass, all animals remained
in good clinical and nutritional condition.
Histology revealed a highly heterogeneous population of
cells, numerous mitotic figures, anisokaryosis, anisocyto-
sis, and several cells containing more than one nucleus;
there was a variable nucleus: plasma ratio (Figures 1, 2).
The centre of the obtained masses showed to be highly
necrotic. Glandular differentiation was present. Immuno-
histochemistry revealed a strong positivity for the Ki67-
antigen (Figure 3); the Ki67 index was between 41% and
48%, respectively
Intraperitoneal Tumours
The group was subdivided in two categories: Animals
receiving 1 × 105 cells, consisting of two males and two
females each, and animals receiving 5 × 105 cells, consist-
ing of three males and three females each. The criteria for
sacrification were impairment of the general condition,
worsening of the nutritional condition, and/or reduction
of activity level. Weight gain was not a reliable factor due
to the development of massive peritoneal effusion.
Table 1: Tumour growth after subcutaneous injection of 1 × 106 
cells of CT1258.
Mean No growth Range SD
[days] [No of animals] [days]
Male 22 1 20–24 1.63
Female 28.75 0 20–42 10.05
Total 25.38 1 20–42 7.58BMC Cancer 2008, 8:240 http://www.biomedcentral.com/1471-2407/8/240
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In all mice receiving 1 × 105 cells tumour growth could be
detected. The mean duration until sacrifice was 28 days. In
one of three females and two of three males inoculated
with 5 × 105 cells tumour growth could be detected, in this
group the mean duration until sacrifice was 26 days
(Table 2). Overall seven out of ten mice intraperitoneally
inoculated with CT1258 developed tumour growth. Of
those animals all but one male, which had received 5 ×
105 cells, had an extended abdomen and proved to have
peritoneal effusion. The male without obvious tumour
growth had developed a thymoma, which was the cause
for the bad clinical condition. Six of these ten mice devel-
oped a mass at the injection site, although at inoculation
a proper amount of time had elapsed until withdrawal of
the needle. Necropsy showed a moderate to high tumour
burden at the peritoneum and no visible signs of metasta-
sis to the lungs (Figure 4). Histological examination of the
obtained masses showed a similar pattern as the subcuta-
neous masses with a glandular differentiation (Figure 5);
staining for Ki67 was strongly positive with a Ki67 index
between 45% and 47%. Isolated populations of tumour
cells could be detected in the lungs, but there was no sign
Diaphragm after i.p. injection of 5 × 105 cells with a high  tumour burden; see Figure 5 for histology; the thoracic  aspect of the diaphragm is not affected Figure 4
Diaphragm after i.p. injection of 5 × 105 cells with a 
high tumour burden; see Figure 5 for histology; the 
thoracic aspect of the diaphragm is not affected.
Subcutaneous mass with multiple mitotic figures and necrotic  area; the large pale cells surrounding the hair follicle are part  of the sebaceous gland and should not be mistaken as  tumour cells (arrow) Figure 2
Subcutaneous mass with multiple mitotic figures and 
necrotic area; the large pale cells surrounding the 
hair follicle are part of the sebaceous gland and 
should not be mistaken as tumour cells (arrow).
Subcutaneous mass with a high mitotic index Figure 1
Subcutaneous mass with a high mitotic index. The 
arrow indicates an atypical mitotic figure.
Ki67 staining of subcutaneous mass with a high amount of  cells staining positively for Ki67 Figure 3
Ki67 staining of subcutaneous mass with a high 
amount of cells staining positively for Ki67.BMC Cancer 2008, 8:240 http://www.biomedcentral.com/1471-2407/8/240
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of vascularisation (Figure 6). In abdominal organs only
peripheral tumour growth could be observed.
Cytogenetic Analysis
The cytogenetic investigation of intraperitoneal and sub-
cutaneous tumours revealed the same markers that have
been shown in analysis of the original tumour and of the
cell line [15]. A hyperdiploid karyotype was present. Cen-
tromeric fusion between chromosomes 1 and 5 (der (1;
5)) and chromosomes 4 and 5 (der (4; 5)) were detected.
A large biarmed marker (mar) was found (Figure 7, 8).
Discussion
Ideally a cell line should not only be immortalized spon-
taneously but also be tumourigenic in experimental ani-
mals. Another claim may be the mimicking of the original
natural behaviour of the tumour in the host. This condi-
tion promotes the predictability of any results obtained
with that very cell line. This is true especially for cell lines
derived from nonhuman tumours if the origin may serve
as a model itself.
This study reveals that the cell line CT1258 is highly
tumourigenic in NOD-Scid mice. Local tumour growth
occurred in 89% of the animals that had received cells
subcutaneously; 86% of the animals that had been inocu-
lated intraperitoneally and that had developed tumour
growth also developed local tumour growth at the injec-
tion site. The latter was not desired, and since it is not
known how many cells remained in the branch canal, the
size of those accidental masses cannot be compared accu-
rately. Focussing on the mice with cells inoculated i.p.,
86% developed peritoneal effusion just as the donor did
and all of them had multiple small nodules within the
serous membranes of the peritoneum rather than one
large mass. The excellent local tumour growth on one
hand and the rapid development of pleural effusion on
the other hand indicates that in studies to come the use of
the cell line might be of a greater value in local adminis-
tration rather than in systemic inoculation. Orthotopic
implantation might be of great value, since this could ena-
ble the assessment of local growth and invasion as well as
potential metastasis. Due to the lack of vascularisation,
the tumour cells found in the lungs of the mice must be
addressed as tumour cell embolism rather than metasta-
sis. Since neither the mice nor the donor had evidence of
lymphogenic or hematogenic metastasis, we conclude
that time for metastasis exceeds the time limitation owed
to local tumour growth. Whether this is due to the rapid
growth rate or due to potentially little disposition of the
cells to degrade extracellular matrix and therefore has a
generally low tendency to metastasise remains unclear.
The absence of bone metastasis is a remarkable fact, which
is contrary to the high incidence of bone metastasis in
Table 2: Tumour growth after intraperitoneal injection of 1 × 105 
and 5 × 105 cells.
Mean No growth Range SD
[days] [No of animals] [days]
Male 26.75 1 24–30 3.2
Female 27.67 2 24–30 3.21
1 × 105 cells 28 0 24–30 2.71
5 × 105cells 26 3 24–30 3.46
Total 27.14 3 24–30 1.12
Diaphragmatic mass (see figure 4 for macroscopic appear- ance) Figure 5
Diaphragmatic mass (see figure 4 for macroscopic 
appearance).
Ki67-staining of tumour cells in the lung; there is no evidence  of vascularisation, therefore these cells are tumour emboli  rather than metastasis Figure 6
Ki67-staining of tumour cells in the lung; there is no 
evidence of vascularisation, therefore these cells are 
tumour emboli rather than metastasis.BMC Cancer 2008, 8:240 http://www.biomedcentral.com/1471-2407/8/240
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canine and human patients [5,19]. Potentially there was
not enough time for bone metastasis to develop due to
rapid local tumour growth, on the other hand, this partic-
ular tumour might have a reduced tendency for skeletal
metastasis. At first glance this reduces the value of the
present tumour model for comparative oncology, but this
interesting feature might be used for further studies
focussing on skeletal metastasis in particular, if the cause
for the absence of metastasis to the skeleton in this other-
wise highly malignant prostate carcinoma is detected. The
tendency to show necrotic areas in the centre might be due
to rapid tumour growth.
The number of cells obviously did not seem not to have a
direct impact on tumour growth, since all mice that had
been inoculated with 1 × 105 cells developed tumours, but
50% of the animals that received 5 × 105 cells did not;
although this is not considered to be statistically signifi-
cant, it suggests that an even lower number of cells might
have been sufficient to induce a tumour. The difference
between male and female animals is not statistically sig-
nificant.
The Ki67 indices in both, the original tumour and the
experimentally induced tumours, were considered to be
high. The difference between the original tumour on one
hand and the subcutaneous and intraperitoneal masses
on the other hand were statistically not significant. In
human medicine a high Ki67 index has shown to be asso-
ciated with a poor prognosis [20]. Considering the histo-
logical characteristics of the described tumour, the high
Ki67 index is not a surprising finding. Comparison of the
Ki67 index of the original tumour to the xenograft
revealed no change in proliferation.
One limiting factor is that two of the nineteen mice in the
study developed thymoma within the course of the study.
This is a frequent finding in older NOD-Scid mice [16,17].
Therefore the animals must not be considered to be
healthy.
Metaphase spread from cells derived from the original canine tumour Figure 7
Metaphase spread from cells derived from the original canine tumour. The arrows indicate the derivative chromo-
somes der (1; 5), der (4; 5) and the marker chromosome mar, which consists of chromosome 1 and chromosome 2 material.
der(4;5)
mar
der(1;5)BMC Cancer 2008, 8:240 http://www.biomedcentral.com/1471-2407/8/240
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Conclusion
The canine prostate carcinoma cell line CT1258 demon-
strated to be tumourigenic in the NOD-Scid mouse.
Tumours induced in mice resembled the biological behav-
iour of the tumour from which the cell line was originally
derived regarding growth pattern and histological appear-
ance. Therefore we conclude that the use of this animal
model will provide results with a high predictability
towards clinical use in veterinary medicine and due to the
correlation between canine and human prostate carci-
noma in humans as well. The lack of skeletal metastasis is
a potential field for further studies.
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